Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Cooper, C.; Bardin, T.; Brandi, M.L.et al.
2016 • In Aging Clinical and Experimental Research, 28 (1), p. 1-16
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders new insights from emerging data. An expert consensus paper ....pdf
[en] Purpose: This consensus review article considers the question of whether glucocorticoid (GC) therapy is still relevant in the treatment of rheumatic diseases, with a particular focus on rheumatoid arthritis (RA), and whether its side effects can be adequately managed. Recent basic
and clinical research on the molecular, cellular and clinical effects of GCs have considerably advanced our knowledge in this field. An overview of the subject seems appropriate.
Methods: This review is the result of a multidisciplinary expert working group, organised by European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. The recent literature was surveyed and the salient evidence synthetized.
Results: The pathophysiological basis of RA (and other inflammatory rheumatic diseases) now strongly implicates the adaptive immune system in addition to innate mechanisms.
The molecular effect of GCs and differential GC sensitivity is better understood, although exploiting this knowledge is still in its infancy. The newer treatment strategies of early and aggressive control of RA have greatly improved clinical outcomes, but improvements are
still possible. Newer targeted anti-inflammatory drugs have made an important impact, yet they too are associated with numerous side effects.
Discussion: Short durations of moderate doses of GCs are generally well tolerated and have a positive benefit/risk ratio. Patients should be assessed for fracture risk and bone preserving agents and be prescribed calcium and vitamin D supplementation.
Conclusions: Within a strategy of a disease modifying approach to inflammatory disease, combination therapy including a GC is effective approach.
Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
Baltimore D (2001) Our genome unveiled. Nature 409(6822):814–816
Boers M (2003) Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 48(7):1771–1774
Grigor C, Capell H, Stirling A et al (2004) Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 364(9430):263–269
Bakker MF, Jacobs JW, Verstappen SM et al (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis. doi:10.1136/ard.2007.078360
Saffar AS, Ashdown H, Gounni AS (2011) The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets 12(4):556–562
Ytterberg AJ, Joshua V, Reynisdottir G et al (2014) Shared immunological targets in the lungs and joints of patients with rheumatoid arthritis: identification and validation. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204912
McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med. doi:10.1056/NEJMra1004965
Miossec P, Korn T, Kuchroo VK (2009) Interleukin-17 and type 17 helper T cells. N Engl J Med. doi:10.1056/NEJMra0707449
Jonsson H, Allen P, Peng SL (2005) Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. Nat Med 11(6):666–671
Turrel-Davin F, Tournadre A, Pachot A et al (2010) FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann Rheum Dis. doi:10.1136/ard.2009
Westwood OM, Nelson PN, Hay FC (2006) Rheumatoid factors: what’s new? Rheumatology (Oxford) 45(4):379–385
Zendman AJ, van Venrooij WJ, Pruijn GJ (2006) Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology (Oxford) 45(1):20–25
Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.24390
Kleyer A, Finzel S, Rech J et al (2013) Bone loss before the clinical onset of rheumatoid arthritis in subjects with anticitrullinated protein antibodies. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202958
Crowson CS, Rahman MU, Matteson EL (2009) Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. J Rheumatol. doi:10.3899/jrheum.081188
Hensvold AH, Magnusson PK, Joshua V et al (2015) Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203947
Wolfe F, Mitchell DM, Sibley JT et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37(4):481–494
Boyer JF, Gourraud PA, Cantagrel A et al (2011) Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine. 78(2):179–183
Wolfe F (2000) The effect of smoking on clinical, laboratory, and radiographic status in rheumatoid arthritis. J Rheumatol 27(3):630–637
Dessein PH, Joffe BI (2006) Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 54(9):2765–2775
Liao KP, Solomon DH (2013) Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford). doi:10.1093/rheumatology/kes243
Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al (2011) Obesity in rheumatoid arthritis. Rheumatology (Oxford) 50(3):450–462
Dougados M, Soubrier M, Antunez A et al (2014) Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). Ann Rheum Dis 73(1):62–68
Wallberg-Jonsson S, Ohman ML, Dahlqvist SR (1997) Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 24(3):445–451
Watson DJ, Rhodes T, Guess HA (2003) All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 30(6):1196–1202
Sihvonen S, Korpela M, Laippala P et al (2004) Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 33(4):221–227
Peters MJ, van Halm VP, Voskuyl AE et al (2009) Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum. doi:10.1002/art.24836
Avina-Zubieta JA, Thomas J, Sadatsafavi M et al (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. doi:10.1136/annrheumdis-2011-20072
Krishnan E, Lingala VB, Singh G (2004) Declines in mortality from acute myocardial infarction in successive incidence and birth cohorts of patients with rheumatoid arthritis. Circulation 110(13):1774–1779
Meune C, Touze E, Trinquart L et al (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). doi:10.1093/rheumatology/kep252
Juni P, Nartey L, Reichenbach S et al (2004) Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364(9450):2021–2029
Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356(24):2457–2471
Trelle S, Reichenbach S, Wandel S et al (2011) Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. doi:10.1136/bmj.c7086
Bensinger SJ, Tontonoz P (2008) Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature. doi:10.1038/nature07202
Toms TE, Panoulas VF, Douglas KM et al (2010) Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk? Ann Rheum Dis. doi:10.1136/ard.2009.115717
Curtis JR, John A, Baser O (2012) Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). doi:10.1002/acr.21693
Toms TE, Panoulas VF, Smith JP et al (2011) Rheumatoid arthritis susceptibility genes associate with lipid levels in patients with rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/ard.2010.144634
del Rincon ID, Williams K, Stern MP et al (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44(12):2737–2745
Turesson C, McClelland RL, Christianson TJ et al (2007) Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 66(1):70–75
Hot A, Lenief V, Miossec P (2012) Combination of IL-17 and TNFalpha induces a pro-inflammatory, pro-coagulant and pro-thrombotic phenotype in human endothelial cells. Ann Rheum Dis. doi:10.1136/annrheumdis-2011-200468
Hot A, Lavocat F, Lenief V et al (2013) Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF-alpha on endothelial cells. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-201887
McCarey DW, McInnes IB, Madhok R et al (2004) Trial of atorvastatin in rheumatoid arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 363(9426):2015–2021
Young SP, Kapoor SR, Viant MR et al (2013) The impact of inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. doi:10.1002/art.38021
Park YB, Choi HK, Kim MY et al (2002) Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am J Med 113(3):188–193
Nadareishvili Z, Michaud K, Hallenbeck JM et al (2008) Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case–control study. Arthritis Rheum. doi:10.1002/art.23935
Doran MF, Crowson CS, Pond GR et al (2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 46(9):2287–2293
Toh ML, Kawashima M, Hot A et al (2010) Role of IL-17 in the Th1 systemic defects in rheumatoid arthritis through selective IL-12Rbeta2 inhibition. Ann Rheum Dis. doi:10.1136/ard.2009.111757
Felson DT, Anderson JJ, Meenan RF (1990) The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two meta analyses. Arthritis Rheum. 33(10):1449–1461
O’Dell JR, Haire CE, Erikson N et al (1996) Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 334(20):1287–1291
Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318
Mottonen T, Hannonen P, Leirisalo-Repo M et al (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164):1568–1573
Svensson B, Boonen A, Albertsson K et al (2005) Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a 2-year randomized trial. Arthritis Rheum 52(11):3360–3370
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al (2005) Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 52(11):3381–3390
Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–339
Vermeer M, Kuper HH, Hoekstra M et al (2011) Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Arthritis Rheum. doi:10.1002/art.30494
Heimans L, Wevers-de Boer KV, Visser K et al (2013) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203243
den Uyl D, Ter Wee M, Boers M et al (2013) A non-inferiority trial of an attenuated combination strategy (‘COBRA-light’) compared to the original COBRA strategy: clinical results after 26 weeks. Ann Rheum Dis. doi:10.1136/annrheumdis-2012-202818
Kirwan JR, Bijlsma JW, Boers M et al (2007) Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 1:CD006356
Gorter SL, Bijlsma JW, Cutolo M et al (2010) Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/ard.2009.127332
Knevel R, Schoels M, Huizinga TW et al (2010) Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/ard.2009.126748
Smolen JS, Aletaha D, Bijlsma JW et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. doi:10.1136/ard.2009.123919
Smolen JS, Landewe R, Breedveld FC et al (2013) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204573
Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204588
Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). doi:10.1002/acr.21641
Curtis JR, Westfall AO, Allison J et al (2006) Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 55(3):420–426
van der Goes MC, Jacobs JW, Boers M et al (2010) Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. doi:10.1136/ard.2009.114579
Saag KG (2012) Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. Bull NYU Hosp Jt Dis 70(Suppl 1):21–25
Santiago T, da Silva JA (2014) Safety of low- to medium-dose glucocorticoid treatment in rheumatoid arthritis: myths and reality over the years. Ann N Y Acad Sci. doi:10.1111/nyas.12428
Saag KG (1997) Low-dose corticosteroid therapy in rheumatoid arthritis: balancing the evidence. Am J Med 103(6A):31S–39S
van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15(6):993–1000
van Staa TP, Leufkens HG, Abenhaim L et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383–1389
da Silva JA, Jacobs JW, Kirwan JR et al (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis 65(3):285–293
Vestergaard P, Olsen ML, Paaske JS et al (2003) Corticosteroid use and risk of hip fracture: a population-based case-control study in Denmark. J Intern Med 254(5):486–493
van Staa TP, Laan RF, Barton IP et al (2003) Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 48(11):3224–3229
Kanis JA, Johansson H, Oden A et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19(6):893–899
Manning LI, Briggs AM, van Doornum DS et al (2013) Glucocorticoid-induced bone loss is associated with abnormal intravertebral areal bone mineral density distribution. Int J Endocrinol. doi:10.1155/2013/768579
Dalle Carbonare L, Arlot ME, Chavassieux PM et al (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. J Bone Miner Res 16(1):97–103
Sambrook PN, Hughes DR, Nelson AE et al (2003) Osteocyte viability with glucocorticoid treatment: relation to histomorphometry. Ann Rheum Dis 62(12):1215–1217
Aeberli D, Schett G (2013) Cortical remodeling during menopause, rheumatoid arthritis, glucocorticoid and bisphosphonate therapy. Arthritis Res Ther. doi:10.1186/ar4180
Harvey NC, Gluer CC, Binkley N et al (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. doi:10.1016/j.bone.2015.05.016
Lems WF, Jacobs JW, Van Rijn HJ et al (1995) Changes in calcium and bone metabolism during treatment with low dose prednisone in young, healthy, male volunteers. Clin Rheumatol 14(4):420–424
Ton FN, Gunawardene SC, Lee H et al (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20(3):464–470
Chan M, Chan PK, Griffith JF et al (2006) Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemical markers of bone metabolism and corticosteroid therapy. Pathology. 38(3):229–235
Kusumbe AP, Ramasamy SK, Adams RH (2014) Coupling of angiogenesis and osteogenesis by a specific vessel subtype in bone. Nature. doi:10.1038/nature13145
Ramasamy SK, Kusumbe AP, Wang L et al (2014) Endothelial Notch activity promotes angiogenesis and osteogenesis in bone. Nature. doi:10.1038/nature13146
van Staa TP, Leufkens HG, Abenhaim L et al (2000) Use of oral corticosteroids in the UK. QJM 93(2):105–111
van Staa TP, Abenhaim L, Cooper C et al (2001) Public health impact of adverse bone effects of oral corticosteroids. Br J Clin Pharmacol 51(6):601–607
Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 339(5):292–299
Cohen S, Levy RM, Keller M et al (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309–2318
Devogelaer JP (2006) Glucocorticoid-induced osteoporosis: mechanisms and therapeutic approach. Rheum Dis Clin North Am 32(4):733–757
van der Goes MC, Jacobs JW, Jurgens MS et al (2013) Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied? Osteoporos Int. doi:10.1007/s00198-012-2073-z
Homik J, Cranney A, Shea B et al (2000) Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2:D001347
Lems WF, Saag K (2015) Bisphosphonates and glucocorticoid-induced osteoporosis: cons. Endocrine. doi:10.1007/s12020-015-0639-1
Silverman S, Curtis J, Saag K et al (2015) International management of bone health in glucocorticoid-exposed individuals in the observational GLOW study. Osteoporos Int. doi:10.1007/s00198-014-2883-2
Souverein PC, Berard A, van Staa TP et al (2004) Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case–control study. Heart 90(8):859–865
Ruyssen-Witrand A, Fautrel B, Saraux A et al (2011) Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review. Joint Bone Spine. doi:10.1016/j.jbspin.2010.02.040
el-Shaboury AH, Hayes TM (1973) Hyperlipidaemia in asthmatic patients receiving long-term steroid therapy. Br Med J 2(5858):85–86
Panthakalam S, Bhatnagar D, Klimiuk P (2004) The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. Scott Med J 49(4):139–141
Fraser R, Ingram MC, Anderson NH et al (1999) Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33(6):1364–1368
Wolfe F, Michaud K (2008) The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case–control analysis. Arthritis Rheum. doi:10.1002/art.23811
Davis JM III, Maradit KH, Crowson CS et al (2007) Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 56(3):820–830
Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A et al (2008) Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 47(1):72–75
Johannesdottir SA, Horvath-Puho E, Dekkers OM et al (2013) Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case–control study. JAMA Intern Med. doi:10.1001/jamainternmed.2013.122
Cutolo M, Seriolo B, Pizzorni C et al (2008) Use of glucocorticoids and risk of infections. Autoimmun Rev. doi:10.1016/j.autrev.2008.07.010
Dixon WG, Kezouh A, Bernatsky S et al (2011) The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study. Ann Rheum Dis. doi:10.1136/ard.2010.144741
Dixon WG, Abrahamowicz M, Beauchamp ME et al (2012) Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case–control analysis. Ann Rheum Dis. doi:10.1136/annrheumdis-2011-200702
Sihvonen S, Korpela M, Mustonen J et al (2006) Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. J Rheumatol 33(9):1740–1746
Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther. doi:10.1186/ar3453
Singh JA, Cameron C, Noorbaloochi S et al (2015) Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. doi:10.1016/S0140-6736(14)61704-9
Silverman MN, Sternberg EM (2008) Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. Neuroimmunomodulation. doi:10.1159/000135620
Kadmiel M, Cidlowski JA (2013) Glucocorticoid receptor signaling in health and disease. Trends Pharmacol Sci. doi:10.1016/j.tips.2013.07.003
Clore JN, Thurby-Hay L (2009) Glucocorticoid-induced hyperglycemia. Endocr Pract. doi:10.4158/EP08331.RAR
Angelopoulos TP, Tentolouris NK, Bertsias GK et al (2014) Steroid-induced diabetes in rheumatologic patients. Clin Exp Rheumatol 32(1):126–130
Iwamoto T, Kagawa Y, Naito Y et al (2004) Steroid-induced diabetes mellitus and related risk factors in patients with neurologic diseases. Pharmacotherapy. 24(4):508–514
Hoes JN, van der Goes MC, van Raalte DH et al (2011) Glucose tolerance, insulin sensitivity and beta-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis. doi:10.1136/ard.2011.151464
den Uyl D, van Raalte DH, Nurmohamed MT et al (2012) Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. doi:10.1002/art.3337
Simard JF, Mittleman MA (2007) Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol 34(3):469–473
Jurgens MS, Jacobs JW, Geenen R et al (2013) Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity? Arthritis Care Res (Hoboken). doi:10.1002/acr.21797
Toms TE, Panoulas VF, Douglas KM et al (2008) Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther. doi:10.1186/ar2578
Babadjanova G, Allolio B, Vollmer M et al (1996) Comparison of the pharmacodynamic effects of deflazacort and prednisolone in healthy subjects. Eur J Clin Pharmacol 51(1):53–57
Saez Barcelona JA, Carmona MM, Navarro LV et al (1999) An open comparison of the diabetogenic effect of deflazacort and prednisone at a dosage ratio of 1.5 mg:1 mg. Eur J Clin Pharmacol 55(2):105–109
Fardet L, Feve B (2014) Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs. doi:10.1007/s40265-014-0282-9
James ER (2007) The etiology of steroid cataract. J Ocul Pharmacol Ther 23(5):403–420
Celojevic D, Carlsson T, Johansson B et al (2012) Cell adhesion molecule expression in human lens epithelial cells after corticosteroid exposure. Open Ophthalmol J. doi:10.2174/1874364101206010042
Chang JR, Koo E, Agron E et al (2011) Risk factors associated with incident cataracts and cataract surgery in the Age-related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology. doi:10.1016/j.ophtha.2011.03.032
Herbert J (2013) Cortisol and depression: three questions for psychiatry. Psychol Med. doi:10.1017/S0033291712000955
Matcham F, Rayner LF, Steer S et al (2013) The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). doi:10.1093/rheumatology/ket169
Matcham F, Norton S, Scott DL et al (2015) Symptoms of depression and anxiety predict treatment response and long-term physical health outcomes in rheumatoid arthritis: secondary analysis of a randomized controlled trial. Rheumatology (Oxford). doi:10.1093/rheumatology/kev306
Dinsen S, Baslund B, Klose M et al (2013) Why glucocorticoid withdrawal may sometimes be as dangerous as the treatment itself. Eur J Intern Med. doi:10.1016/j.ejim.2013.05.014
Fardet L, Nazareth I, Whitaker HJ et al (2013) Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. doi:10.4088/JCP.12m08034
Debono M, Ross RJ (2011) Optimal glucocorticoid therapy. Endocr Dev. doi:10.1159/000321241
Cutolo M, Iaccarino L, Doria A et al (2013) Efficacy of the switch to modified-release prednisone in rheumatoid arthritis patients treated with standard glucocorticoids. Clin Exp Rheumatol 31(4):498–505
Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis. doi:10.1136/annrheumdis-2011-201067
Emkey RD, Lindsay R, Lyssy J et al (1996) The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. Arthritis Rheum 39(2):277–282
Axelsen MB, Eshed I, Horslev-Petersen K et al (2015) A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204537
Osamura H (1982) Penetration of topical corticosteroids through human epidermis. J Dermatol 9(1):45–58
Vestergaard P, Rejnmark L, Mosekilde L (2005) Fracture risk associated with systemic and topical corticosteroids. J Intern Med 257(4):374–384
Derendorf H, Mollmann H, Gruner A et al (1986) Pharmacokinetics and pharmacodynamics of glucocorticoid suspensions after intra-articular administration. Clin Pharmacol Ther 39(3):313–317
Dernis E, Ruyssen-Witrand A, Mouterde G et al (2010) Use of glucocorticoids in rheumatoid arthritis—pratical modalities of glucocorticoid therapy: recommendations for clinical practice based on data from the literature and expert opinion. Joint Bone Spine. doi:10.1016/j.jbspin.2009.12.010
Yoon SH, Lee HY, Lee HJ et al (2013) Optimal dose of intra-articular corticosteroids for adhesive capsulitis: a randomized, triple-blind, placebo-controlled trial. Am J Sports Med. doi:10.1177/0363546513480475
Pereira RM, Freire de Carvalho CJ (2011) Glucocorticoid-induced myopathy. Joint Bone Spine. doi:10.1016/j.jbspin.2010.02.025
Buttgereit F, Burmester GR, Lipworth BJ (2005) Optimised glucocorticoid therapy: the sharpening of an old spear. Lancet 365(9461):801–803
van der Laan S, Meijer OC (2008) Pharmacology of glucocorticoids: beyond receptors. Eur J Pharmacol. doi:10.1016/j.ejphar.2008.01.060
De Bosscher K, Haegeman G, Elewaut D (2010) Targeting inflammation using selective glucocorticoid receptor modulators. Curr Opin Pharmacol. doi:10.1016/j.coph.2010.04.007
Barnes PJ, Adcock IM (2009) Glucocorticoid resistance in inflammatory diseases. Lancet. doi:10.1016/S0140-6736(09)60326-3
Biddie SC, Conway-Campbell BL, Lightman SL (2012) Dynamic regulation of glucocorticoid signalling in health and disease. Rheumatology (Oxford). doi:10.1093/rheumatology/ker215
Quax RA, Koper JW, de Jong PH et al (2012) In vitro glucocorticoid sensitivity is associated with clinical glucocorticoid therapy outcome in rheumatoid arthritis. Arthritis Res Ther. doi:10.1186/ar4029
Barnes PJ (2011) Glucocorticosteroids: current and future directions. Br J Pharmacol. doi:10.1111/j.1476-5381.2010.01199.x
van Oosten MJ, Dolhain RJ, Koper JW et al (2010) Polymorphisms in the glucocorticoid receptor gene that modulate glucocorticoid sensitivity are associated with rheumatoid arthritis. Arthritis Res Ther. doi:10.1186/ar3118
Quax RA, Koper JW, Huisman AM et al (2015) Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis. Rheumatol Int. doi:10.1007/s00296-015-3235-z
Sorrells SF, Sapolsky RM (2007) An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 21(3):259–272
Harbuz MS, Jessop DS (1999) Is there a defect in cortisol production in rheumatoid arthritis? Rheumatology (Oxford) 38(4):298–302
Cutolo M, Foppiani L, Minuto F (2002) Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. J Endocrinol Invest 25(10 Suppl):19–23
Straub RH, Bijlsma JW, Masi A et al (2013) Role of neuroendocrine and neuroimmune mechanisms in chronic inflammatory rheumatic diseases–the 10-year update. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.04.008
Devogelaer JP, Goemaere S, Boonen S et al (2006) Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 17(1):8–19
Grossman JM, Gordon R, Ranganath VK et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). doi:10.1002/acr.20295
Weinstein RS (2011) Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. doi:10.1056/NEJMcp1012926
Lekamwasam S, Adachi JD, Agnusdei D et al (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. doi:10.1007/s00198-012-1958-1
Hoes JN, Jacobs JW, Boers M et al (2007) EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 66(12):1560–1567
Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-203249
Kanis JA, McCloskey EV, Johansson H et al (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. doi:10.1007/s00198-012-2074-y
Eastell R, Krege JH, Chen P et al (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22(1):61–66
Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66(9):1137–1142
Sans S, Kesteloot H, Kromhout D (1997) The burden of cardiovascular diseases mortality in Europe. Task Force of the European Society of Cardiology on Cardiovascular Mortality and Morbidity Statistics in Europe. Eur Heart J 18(12):1231–1248
Solomon DH, Greenberg J, Curtis JR et al (2015) Derivation and Internal Validation of an Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis: a Consortium of Rheumatology Researchers of North America Registry Study. Arthritis Rheumatol. doi:10.1002/art.39195
van der Goes MC, Jacobs JW, Boers M et al (2010) Monitoring adverse events of low-dose glucocorticoid therapy: EULAR recommendations for clinical trials and daily practice. Ann Rheum Dis. doi:10.1136/ard.2009.124958
Fardet L (2013) Long term glucocorticoid therapy: so much remains to be done…. Rev Med Intern. doi:10.1016/j.revmed.2013.02.017
Clark AR (2007) Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 275:79–97. doi:10.1016/j.mce.2007.04.013
